Video Summary - PDD-UKTPT Video Pengajaran-Serdos-Muchlis Achsan Udji Sofro

Main ideas & lessons conveyed

Purpose of the lecture

Topic: Diagnosis and management of HIV infections (within “tropical infections” teaching).
Learning goal: Students (stage 2, year 2 specialist doctor education program) should be able to formulate disease management using clinical skills and field planning, specifically for HIV.

HIV/AIDS epidemiology in Indonesia

Over the last decade, reported HIV cases generally increased, with a notable dip in 2020 attributed to COVID-19-related fear of seeking care/testing.

COVID-19 impact on HIV/AIDS trends

HIV patients may experience worse outcomes if co-infected with COVID-19 due to additional inflammatory burden.
Although HIV case numbers fell in 2020, AIDS increased afterward, suggesting delayed detection/care and worse progression risk.

Age and sex distribution

In 2022, the largest number of cases was in reproductive age 25–49.
In 2023 (and concerns toward 2025), men having sex with men is described as a high-concern group.

Why HIV cases may be increasing

Greater active case finding by healthcare workers.
Increased public knowledge about HIV.
Normalization of HIV testing (reduced stigma; accepted similarly to other tests such as blood sugar).
The lecture also emphasizes that prevention/transmission risk behaviors may be widely tolerated in society.

Transmission risk & societal/behavioral factors (prevention challenges)

Unsafe sex and “sex outside the wife” described as socially normalized.
Sex between men and sex before marriage described as increasingly tolerated.
Indirect commercial sex networks (e.g., via venues) are discussed as part of real-world risk patterns.

Example mentioned from Wonosobo

1,150 female indirect sex workers assisted by NGOs.
10% (115) HIV-positive among the group.
Of those HIV-positive cases:
- 5 had STIs
- 25 were actively serving customers (as described)

Condom availability vs. consistent use

Condom availability is acknowledged, but consistent condom use is portrayed as difficult due to reluctance and social/behavioral barriers.

Clinical course of HIV infection (phases and timing)

Acute phase (first ~3 months, described)
- High viral replication
- Easier transmission
Asymptomatic / latent phase
- Up to 6–7 years without clear symptoms
AIDS phase
- Often around the 7th year (as described)
- Secondary/opportunistic infections appear

Pathogenesis & the “window period” (diagnostic reasoning)

Where the virus enters after sex (lecturer explanation)

Entry site after sexual intercourse:
- The tip of the penis and vagina
Early capture:
- Captured by dendritic cells in mucous membrane early (first 2 days)
Timing effect on tests:
- If someone tests the next day after risky sex, results may be negative because antibodies haven’t formed yet.

Window period (test timing)

Window period: time from infection start until detectable HIV antibodies.
Lecturer’s ranges:
- Antibodies may become detectable around day 12 (minimum described point).
- Antibody window is described as up to ~25 days.
Older claims of longer windows (e.g., months) are noted, but the lecturer states latest research points to up to 25 days.

Acute HIV symptoms (when they may appear)

Approximately 15–25 days after exposure:
- Fever
- General body discomfort
- Muscle aches
- Headache
- Red spots/rash
- Sometimes sore throat
- Possible enlarged lymph nodes in the neck

Practical point: If a patient had recent risky exposure, clinicians can advise testing at ~15 days for early detection (as stated in the lecture).

Transmission pillars (what must occur for HIV to spread)

The lecturer states HIV transmission requires three pillars:

Exit from damaged mucosa
- Damage may occur in the vagina, tip of the penis, and anus.
- Without mucosal damage, transmission is less likely.
An intermediary fluid
- Blood, vaginal fluid, semen/sperm, etc. (as relevant fluids)
Entry into the infected/damaged site
- Virus must reach susceptible tissue/entry through the infected/damaged area.

Additional clarification:

Condom use is repeatedly emphasized as prevention.
STIs increase risk by causing mucosal damage (e.g., vaginitis).

Example about a serodiscordant couple

Hospital example (Dr. Kariadi’s Central General Hospital):
- A woman is HIV-positive; husband is HIV-negative.
- Husband stays negative because:
  - No STI-related mucosal damage and sex only with his wife
  - Wife takes regular medication, and safe sex occurs consistently
Key logic presented:
- Transmission is not guaranteed unless the “pillars” align and viral replication is not suppressed.

HIV life cycle overview (as described)

HIV targets T lymphocytes via CD4 receptors.
Core interactions involve GP120/GP41 and co-receptors CCR5/CXCR4.
After entry:
- Viral RNA is converted into DNA (via reverse transcriptase).
- HIV DNA integrates into host DNA.
- Viral messenger RNA is produced to make viral components.
- Protease helps process viral proteins.
- New virions form and exit the cell.
Consequence:
- Infected lymphocytes die → CD4 declines while viral numbers rise unless treated.

Diagnosis workflow (stepwise testing strategy)

Multi-test algorithm described

Test 1
- If reactive → proceed
- If non-reactive → final considered non-reactive (in the described lab context)
Test 2
- If reactive → proceed
- If any component becomes non-reactive → final classification becomes inconclusive
Test 3
- If reactive → final is reactive
- If not all match reactivity → diagnosis cannot be concluded

Sample type issue

HIV diagnosis should be based on blood.
Saliva/urine “rapid tests” are described as likely detecting antibodies only and still require blood confirmation.
Practical Q&A:
- If a rapid test is negative despite suspicion → repeat after 14 days (2 weeks).

Mother-to-child transmission prevention (PMTCT)

Child delivery guidance (timeline and regulation)

Past mention (as stated):
- In 2013, delivery by cesarean section was mentioned.
Current guidance (as stated):
- Ministry of Health Regulation 2019: cesarean should be based on medical indications, such as:
  - Narrow pelvis
  - Premature rupture of membranes
  - Placenta previa
  - Labor not progressing
Cesarean may be avoided if:
- Mother has taken ARV for at least 6 months
- Viral load is undetectable
- Decision follows medical indications

Screening mandate

Lecturer states:
- All pregnant women should be tested for HIV and syphilis.

Effect of ARV adherence on transmission risk

Without adequate ARV adherence: transmission risk ~40%
With regular ARV use: risk decreases to ~8%

Infant testing note

Example given:
- A child was negative after testing at 18 months (as described)

Disease progression variability (host factors)

Progression depends on:
- Virus strain
- Host factors
Categories described:
- Rapid progressors
- Intermediate progressors
- Typical/all progressors (as described: long variability)
Example:
- A mother infected earlier then stopped medication.
- Another case described slow progression over many years until opportunistic infection appeared—illustrating AIDS may not develop immediately.

Treatment management steps (ARV + opportunistic infection coordination)

Key rule presented: prioritize opportunistic infection treatment when needed

Ordering logic (as described):
- If an OI exists:
  - TB treatment first if TB coexists with HIV
  - After ~2 weeks, start ARV
- Exception mentioned: meningitis
  - ARV timing at at least 4 weeks (as described)
After TB therapy starts:
- ARV is continued later based on these timing rules.

Additional OI example: cryptococcal disease

If CD4 < 200, start cryptococcal management after the stated sequence (including after 6 weeks as mentioned).

TB prevention / prophylaxis

Notes:
- TB prevention therapy for HIV patients without active OI
- Also applies to pregnant women, children, and those who completed TB treatment

Antiretroviral regimen details (as mentioned)

A specific regimen described includes:
- Lamivudine plus a “double component” (unclear due to subtitle garbling)
- “One tablet per day for life” (as phrased by the lecturer)
Additional dosing schedule described (subtitle wording partially garbled), including examples such as:
- 300 ml per 24 hours for 6 months
- 3 tablets per week for 3 months
Overall concept emphasized:
- Long-term therapy with lifelong treatment once started.

Monitoring, adherence, viral suppression, and treatment failure

Viral load expectations

After starting ARV:
- Viral load may initially be high,
- Then should become undetectable with effective treatment.
“Undetectable” means:
- Virus is present but so low it’s not detected by tests.

Monitoring schedule (as described)

Monthly clinical monitoring
- Weight and symptoms
- Signs such as oral fungal infection (“fungus in the mouth”)
CD4 / TB-related checks
- Every 6 months (as stated)
Viral load
- Every year after continuation (as stated)

Importance of adherence and dropout risk

Warning:
- In the first 2 years, patients may become complacent and drop out after feeling healthy.
- If medication stops, viral load can rise again.

When treatment failure is suspected

Criteria mentioned:
- Viral count remains >1000 after ~3 months
Next steps (as described):
- Reassess adherence first
- If adherence is adequate and failure persists → move to second-line regimen

Resistance and regimen switching

Lecturer notes:
- Some patients may develop resistance to first-generation agents.
- Use second-generation drugs/regimen replacement when needed.

Side effects mentioned (general)

Common side effects described for one drug class:
- Headaches
- Toxic liver disorders / liver issues
Practical management:
- Monitoring and switching to an alternative drug if needed
GI effects:
- Nausea/vomiting; supportive stomach medication may be added

Q&A at end (practical clinical questions)

Q: Suspected HIV but rapid test negative—when to repeat?
- A: Repeat after 14 days (2 weeks).
Q: Why efavirenz replaced with “double …” (garbled)?
- A: Due to side-effect profile:
  - ~70% headaches (even after years in some cases)
  - Switching recommended in certain monitored cases
  - But ~30% side effects may still be manageable depending on tolerance and the ability to monitor GI side effects.

Speakers / sources featured

Mukhlis / Muchlis Achsan Udji Sofro (primary lecturer; referenced multiple ways)
Indonesian Ministry of Health (epidemiology trends and age-group data)
Dr. Kariadi’s Central General Hospital (hospital context example)
Ministry of Health Regulation 2019 (cesarean indications and PMTCT guidance)
NGOs (assisting sex worker groups in Wonosobo; no specific names)
COVID-19 (context for changes in testing/health-seeking behavior in 2020)

PDD-UKTPT Video Pengajaran-Serdos-Muchlis Achsan Udji Sofro

Key takeaways